Posts

NImmune and BioTherapeutics partner on precision medici...

NImmune Biopharma and BioTherapeutics have partnered to develop new precision me...

Evotec partners X-Chem for tech-enabled drug discovery

German life science company Evotec has announced a collaboration with X-Chem to ...

FDA approves Amneal and Shilpa’s oncology product BORUZU

The US FDA has approved Amneal Pharmaceuticals and Shilpa Medicare’s oncology pr...

Biogen’s higher Spinraza dose shows better efficacy in ...

Biogen plans to apply for regulatory approval of this investigational dose regim...

After failed FSGS bid, Travere wins full FDA approval f...

The company had focused its resources on Filspari’s launch in IgAN after the US ...

Onward awarded $1.1M grant from the Christopher & Dana ...

Onward Medical revealed that it has received a major grant from the Christopher ...

Illumina Gets Favorable Decision Regarding Grail Acquis...

In a decision expected to limit Brussels’ merger authority, American gene sequen...

Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase ...

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of th...

Phase 2/3 of Athira Trial for Alzheimer’s Fails

Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The tr...

NHS England offers MSD belzutifan for von Hippel-Lindau...

NHS England has announced the availability of MSD UK’s belzutifan, a take-at-hom...

UK bans xylazine and 21 other substances to fight drug ...

The UK government has taken a step towards banning xylazine and 21 other substan...

ArsenalBio secures $325m to develop cell therapy progra...

ArsenalBio has secured $325m in a Series C financing round to propel its program...

Lilly and EVA Pharma to expand baricitinib access in Af...

Eli Lilly and EVA Pharma have formed a partnership to increase the availability ...

ESC 2024: Insights into RNA as therapeutic target and tool

A panel of researchers gave presentations on the clinical evidence for the role ...

ESC 2024: New PACMAN-AMI trial analysis sheds insights ...

The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeut...